Thymosin Alpha-1
Regulatory
Legal Status in 2026
Compounding restricted under the FDA 503A bulk-substance list.
Federal law restricts compounding of this compound. For compounds whose FDA-declared shortage has resolved, Section 503B bulk compounding rights have ended; Section 503A compounding remains possible only with a documented patient-specific clinical justification (a verified allergy to an inactive ingredient, or a strength the manufacturer does not make, not cost or convenience). For compounds affirmatively excluded by the FDA's Pharmacy Compounding Advisory Committee, compounding is not permitted under the bulk-substance list. The FDA-approved product (where one exists) is the appropriate default.
About
About Thymosin Alpha-1
Thymosin Alpha-1 (Tα1) is an endogenous thymic peptide with potent immunomodulatory and antiviral properties, approved in 37 countries for hepatitis B, hepatitis C, and as an immune adjuvant in cancer care. It is used in optimization medicine for immune restoration, chronic infection management, and as an adjunct in post-COVID recovery. Compounded Tα1 is available through US pharmacies. It has an exceptional safety profile with decades of clinical use.
Science
Mechanism of Action
Stimulates maturation and differentiation of T-cells, enhances NK cell activity, upregulates MHC class I expression on cells, and modulates Th1/Th2 cytokine balance — producing a broad immunostimulatory effect without autoimmune risk.
Dosing
Typical Protocol
1.6 mg subcutaneous injection 2x weekly for 6–12 months for immune restoration; shorter cycles used for acute protocols.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard: effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
Compounded Thymosin Alpha-1 is restricted. Pharmacies can't legally make it under the FDA's compounding rules. If an FDA-approved version exists, that is the legal channel. We don't list sellers here because we can't verify which ones stay inside those rules.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.